Human Recombinant MET - His Tagged
Reference ID:KB-3683
Western Blot
Flow Cytometry
Gene of Interest
Gene Synonyms:MET
Protein Names:Hepatocyte growth factor receptor (HGF receptor) (EC (HGF/SF receptor) (Proto-oncogene c-Met) (Scatter factor receptor) (SF receptor) (Tyrosine-protein kinase Met)
Accession Data
Organism:Homo sapiens (Human)
Mass (kDa):1555.41
Length (aa):1390
Proteomics (Proteome ID):UP000005640
Proteomics (Chromosome): Chromosome 7
Active Site:ACT_SITE 1204 1204 Proton acceptor. {ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE-ProRule:PRU10028}.
Activity Regulation: In its inactive state, the C-terminal tail interacts with the catalytic domain and inhibits the kinase activity. Upon ligand binding, the C-terminal tail is displaced and becomes phosphorylated, thus increasing the kinase activity.
Binding Site:BINDING 1110 1110 ATP.
Catalytic Activity: Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-[protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=; Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
Function [CC]:Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. May regulate cortical bone osteogenesis (By similarity). {ECO:0000250|UniProtKB:P16056}.; (Microbial infection) Acts as a receptor for Listeria monocytogenes internalin InlB, mediating entry of the pathogen into cells. {ECO:0000269|PubMed:11081636, ECO:0000305|PubMed:17662939, ECO:0000305|PubMed:19900460}.
Nucleotide Binding:NP_BIND 1084 1092 ATP. {ECO:0000255|PROSITE-ProRule:PRU00159}.
Site:SITE 307 308 Cleavage. {ECO:0000255}.; SITE 1003 1003 Required for ligand-induced CBL-mediated ubiquitination. {ECO:0000269|PubMed:12244174}.; SITE 1009 1010 Breakpoint for translocation to form TPR-MET oncogene.
Tissue Specificity:Expressed in normal hepatocytes as well as in epithelial cells lining the stomach, the small and the large intestine. Found also in basal keratinocytes of esophagus and skin. High levels are found in liver, gastrointestinal tract, thyroid and kidney. Also present in the brain. Expressed in metaphyseal bone (at protein level) (PubMed:26637977). {ECO:0000269|PubMed:1719465, ECO:0000269|PubMed:1917129, ECO:0000269|PubMed:26637977}.
Chemical Profile | ChEBI:H(+) [CHEBI:15378]; ATP [CHEBI:30616]; L-tyrosine residue [CHEBI:46858]; L-tyrosine-phosphate residue [CHEBI:82620]; ADP [CHEBI:456216]
ChEBI (Catalytic Activity):H(+) [CHEBI:15378]; ATP [CHEBI:30616]; L-tyrosine residue [CHEBI:46858]; L-tyrosine-phosphate residue [CHEBI:82620]; ADP [CHEBI:456216]
Disease:Note=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.; Note=Defects in MET may be associated with gastric cancer.; Hepatocellular carcinoma (HCC) [MIM:114550]: A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes. {ECO:0000269|PubMed:9927037}. Note=The disease is caused by mutations affecting the gene represented in this entry.; Renal cell carcinoma papillary (RCCP) [MIM:605074]: A subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. {ECO:0000269|PubMed:10327054, ECO:0000269|PubMed:10417759, ECO:0000269|PubMed:10433944, ECO:0000269|PubMed:9140397, ECO:0000269|PubMed:9563489}. Note=The disease is caused by mutations affecting the gene represented in this entry.; Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.; Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.; Deafness, autosomal recessive, 97 (DFNB97) [MIM:616705]: A form of non-syndromic sensorineural hearing loss with prelingual onset. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. {ECO:0000269|PubMed:25941349}. Note=The disease is caused by mutations affecting the gene represented in this entry.; Osteofibrous dysplasia (OSFD) [MIM:607278]: A congenital disorder of osteogenesis characterized by non-neoplastic, radiolucent lesions that affect the cortical bone immediately under the periosteum. It usually manifests as a painless swelling or anterior bowing of the long bones, most commonly the tibia and fibula. {ECO:0000269|PubMed:26637977}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Disease-associated variants identified in 4 families cause the deletion of exon 14. This results in the exclusion of an ubiquitination target site within the cytoplasmic domain, hence in protein stabilization. The persistent presence of MET at the cell surface in conditions of ligand-dependent activation retards osteoblastic differentiation. {ECO:0000269|PubMed:26637977}.
Mutagenesis:MUTAGEN 1234 1234 Y->F: Complete loss of kinase activity and of ligand-induced ubiquitination. Alters interaction with PTPN1 and PTPN2. Loss of interaction with PTPN1 and PTPN2; when associated with F-1235. {ECO:0000269|PubMed:12244174, ECO:0000269|PubMed:18819921}.; MUTAGEN 1235 1235 Y->F: Complete loss of kinase activity. Alters interaction with PTPN1 and PTPN2. Loss of interaction with PTPN1 and PTPN2; when associated with F-1234. {ECO:0000269|PubMed:12244174, ECO:0000269|PubMed:18819921}.; MUTAGEN 1313 1313 Y->F: No effect on ligand-induced CBL-mediated ubiquitination; when associated with F-1349, F-1356 and F-1365. {ECO:0000269|PubMed:12244174}.; MUTAGEN 1349 1349 Y->F: No effect on ligand-induced CBL-mediated ubiquitination; when associated with F-1313, F-1356 and F-1365. {ECO:0000269|PubMed:12244174}.; MUTAGEN 1356 1356 Y->F: No effect on ligand-induced CBL-mediated ubiquitination; when associated with F-1313, F-1349 and F-1365. {ECO:0000269|PubMed:12244174}.; MUTAGEN 1365 1365 Y->F: No effect on ligand-induced CBL-mediated ubiquitination; when associated with F-1313, F-1349 and F-1356. {ECO:0000269|PubMed:12244174}.
Reagent Data
Name:HGF R
Class:Growth Factor
Region:Glu 25 - Thr 932
Molecular Weight:32.5 (? chain) and 60 (? chain)
Purification System:Chromatography
Formulation:Sterile-filtered colorless solution
Formulation Concentration:1 mg/ml
Buffer Volume:Standard
Buffer Solution:PBS
Endotoxin Level:< 1%
Aggregate Tested By:SDS-PAGE
Endotoxin Screened:< 0.1 ng/ug
Purity:> 98%
Determined: SDS-PAGE
Validated: RP-HPLC
Sample Handling
Stability:This bioreagent is stable at 4°C (short-term) and -70°C(long-term). After reconstitution, sample may be stored at 4°C for 2-7 days and below -18°C for future use.
Preparation:Reconstitute in sterile distilled H2O to no less than 100 ug/ml; dilute reconstituted stock further in other aqueous solutions if needed. Please review COA for lot-specific instructions. Final measurements should be determined by the end-user for optimal performance.